Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
In its lawsuit, the OFA said that the FDAs decision to end the shortage was a reckless and arbitrary move and could deprive patients of a vital treatment for type 2 diabetes and obesity. In an interview with BioSpace last month, David Rosen, partner at Foley & Lardner, said that the lawsuit is a precedent in this area. Prior to the OFA suit, no one has ever challenged the FDAs decision to remove a therapy from the drug shortage list. The OFA case is still ongoing, with the next court update due on Thursday
doi:10.1056/NEJMoa2032183 Lempesis IG, Liu J, Dalamaga M
Shapsis now offers Virtual Consultations for patients across Jacksonville, FL, making professional guidance accessible from the comfort of your home
Incidence rates (IRs) of outcomes per 1,000 person-years were estimated
